Available Trials

• Breast
• Hematology
• Leukemia
• Lung - Non-Small Cell Lung
• Lymphoma
• Pancreas
• PNH

Breast

• NEW: USOR 18042 A Phase 2, Non-Randomized, Open Label, Single Arm, Multi-Center Study Of Talazoparib For Neoadjuvant Treatment Of Germline BRCA 1/2 Mutation Patients With Early Triple-Negative Breast Cancer. (C3441020)

  Available at: Niles, Arlington Heights

  ---

Hematology

• USOR 08160 PNH Registry: Primary Objective of the Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry will Collect Data to Evaluate Safety Data Specific to the Use of Solaris and to Characterize the Progression of PNH as well as Clinical Outcomes, Mortality and Morbidity in Solaris and Non-Solaris Treated Patients. Secondary Objective is Raising PNH Awareness in the Medical Community and Patient/Potential Patient Population. (M07-001)

  Available at: Niles, Arlington Heights

  ---

Leukemia

• NOW OPEN: USOR 18155 A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL.) (BGB-3111-305)

  Available at: Arlington Heights, Niles

  ---

• AGIOS AG120-C-009 A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects 18 Years of Age and Older, with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation.

  Available at: Niles, Arlington Heights

  ---

Lung - Non-Small Cell Lung

• USOR 16156 A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer. (CA209-817)

  Available at: Niles, Arlington Heights

  ---

Lymphoma

• NOW OPENED: USOR 18132 A Phase 2, Open-Label Study of Zanubrutinib (BGB-3111) in Patients with Relapsed or Refractory Marginal Zone Lymphoma. (BGB-3111-214)

  Available at: Niles

  ---

• USOR 17093/CITADEL-205 A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Ka Inhibitor, In Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205) - INCB050465-205.

  Available at: Niles, Arlington Heights

  ---

• USOR 16065 Relapsed/Refractory - A Phase 2b, Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 and TGR-1202 Alone in Patients with Previously Treated Diffuse Large B-Cell Lymphoma. (UTX-TGR-205)

  Available at: Niles, Arlington Heights

  ---

• USOR 11282 1st Line - A Phase 2, Single-Arm, Open-Label Study of Single-Agent Brentuximab Vedotin for Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above.(SGN35-015)

  Available at: Niles

  ---

• USOR 16100 Hodgkins Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices. (CA20965)

  Available at: Niles, Arlington Heights

  ---

Pancreas

• NEWLY OPENED USOR 17160 / PANOVA-3: Pivotal, Randomized, Open-Label Study of Tumor Testing Fields (TTFields, 150kHz) concomitant with Gemcitabine and Nab-Paclitaxel for Front-Line Treatment of Locally-Advanced Pancreatic Adenocarcinoma (EF-27)

  Available at: Niles, Arlington Heights

  ---

PNH

• USOR 08160 PNH Registry: Primary Objective of the Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry will Collect Data to Evaluate Safety Data Specific to the Use of Solaris and to Characterize the Progression of PNH as well as Clinical Outcomes, Mortality and Morbidity in Solaris and Non-Solaris Treated Patients. Secondary Objective is Raising PNH Awareness in the Medical Community and Patient/Potential Patient Population. (M07-001)

  Available at: Niles, Arlington Heights

  ---